Skip to main content
Erschienen in: Diabetologia 3/2007

01.03.2007 | Article

Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy—a nationwide 5-year-study in Japan

verfasst von: Y. Murase, A. Imagawa, T. Hanafusa, H. Iwahashi, Y. Uchigata, A. Kanatsuka, E. Kawasaki, T. Kobayashi, A. Shimada, I. Shimizu, T. Maruyama, H. Makino

Erschienen in: Diabetologia | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The aim of the present study was to assess the development of microangiopathy in patients with fulminant type 1 diabetes, a novel subtype of type 1B diabetes.

Materials and methods

In a nationwide survey, we followed 41 patients with fulminant type 1 diabetes and 76 age- and sex-matched patients with type 1A diabetes for 5 years. The following data were recorded every 12 months after the onset of diabetes: seven-point blood glucose concentrations, HbA1c level, urinary albumin excretion, serum C-peptide level, blood pressure, daily dosages of insulin, frequency of severe hypoglycaemic episodes, and neurological and fundoscopic examination.

Results

The 5-year cumulative incidence of microangiopathy was 24.4% in fulminant type 1 diabetes and 2.6% in type 1A diabetes. In longitudinal studies using the Kaplan–Meier method, the cumulative incidence of each form of microangiopathy was significantly higher in fulminant type 1 diabetes than in type 1A diabetes; retinopathy was 9.8% vs 0% (p = 0.014), nephropathy 12.2% vs 2.6% (p = 0.015) and neuropathy 12.2% vs 1.3% (p = 0.010), respectively. Mean HbA1c levels were similar in the fulminant and type 1A diabetes groups during the follow-up periods. However, the mean M-value, mean insulin dosages and the frequency of severe hypoglycaemic episodes were significantly higher, and the mean postprandial C-peptide level was significantly lower in the fulminant type 1 diabetes group.

Conclusions/interpretation

These data suggest that patients with fulminant type 1 diabetes are a high-risk subgroup for diabetic microangiopathy associated with the lack of endogenous insulin secretion from the onset of diabetes.
Literatur
1.
Zurück zum Zitat The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197
2.
Zurück zum Zitat Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
3.
Zurück zum Zitat Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342:301–307PubMedCrossRef Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342:301–307PubMedCrossRef
4.
Zurück zum Zitat Imagawa A, Hanafusa T, Uchigata Y et al (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26:2345–2352PubMed Imagawa A, Hanafusa T, Uchigata Y et al (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26:2345–2352PubMed
5.
Zurück zum Zitat Shimizu I, Makino H, Imagawa A et al (2006) Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab 91:471–476PubMedCrossRef Shimizu I, Makino H, Imagawa A et al (2006) Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab 91:471–476PubMedCrossRef
6.
Zurück zum Zitat Imagawa A, Hanafusa T, Uchigata Y et al (2005) Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 48:294–300PubMedCrossRef Imagawa A, Hanafusa T, Uchigata Y et al (2005) Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 48:294–300PubMedCrossRef
7.
Zurück zum Zitat Kent LA, Gill GV, Williams G (1994) Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis. Lancet 344:778–781PubMedCrossRef Kent LA, Gill GV, Williams G (1994) Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis. Lancet 344:778–781PubMedCrossRef
8.
Zurück zum Zitat Matsumoto A, Iwashima Y, Abiko A et al (2000) Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy. Diabetes Res Clin Pract 50:195–202PubMedCrossRef Matsumoto A, Iwashima Y, Abiko A et al (2000) Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy. Diabetes Res Clin Pract 50:195–202PubMedCrossRef
9.
Zurück zum Zitat Klein R, Klein BEK, Magli YL, Brothers RJ, Meuer SM, Davis MD (1986) An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183–1187PubMed Klein R, Klein BEK, Magli YL, Brothers RJ, Meuer SM, Davis MD (1986) An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183–1187PubMed
10.
Zurück zum Zitat Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL (1989) The Wisconsin Epidemiologic Study of Diabetic Retinopathy IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107:237–243PubMed Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL (1989) The Wisconsin Epidemiologic Study of Diabetic Retinopathy IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107:237–243PubMed
11.
Zurück zum Zitat Henricsson M, Nystrom L, Blohme G et al (2003) The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26:349–354PubMed Henricsson M, Nystrom L, Blohme G et al (2003) The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26:349–354PubMed
12.
Zurück zum Zitat American Diabetes Association (2004) Nephropathy in diabetes (position statement). Diabetes Care 27(Suppl 1):S79–S83 American Diabetes Association (2004) Nephropathy in diabetes (position statement). Diabetes Care 27(Suppl 1):S79–S83
13.
Zurück zum Zitat Shima K, Endo J, Oimomi M, Oshima I, Omori Y, Katayama Y (1994) Inter-laboratory difference in HbA1c measurement in Japan. A report of the Committee on an inter-laboratory standarization of HbA1c determination, the Japan Diabetes Society. J Jpn Diabetes Soc 37:855–864 (in Japanese) Shima K, Endo J, Oimomi M, Oshima I, Omori Y, Katayama Y (1994) Inter-laboratory difference in HbA1c measurement in Japan. A report of the Committee on an inter-laboratory standarization of HbA1c determination, the Japan Diabetes Society. J Jpn Diabetes Soc 37:855–864 (in Japanese)
14.
Zurück zum Zitat Roberts WL, Calcote CB, Cook CB et al (1998) Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens. Clin Chim Acta 273:21–33PubMedCrossRef Roberts WL, Calcote CB, Cook CB et al (1998) Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens. Clin Chim Acta 273:21–33PubMedCrossRef
15.
Zurück zum Zitat Schlichtkrull J, Munch O, Jersild M (1954) The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 177:95–102CrossRef Schlichtkrull J, Munch O, Jersild M (1954) The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 177:95–102CrossRef
16.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
17.
Zurück zum Zitat Diabetes Control and Complications Trial Research Group (1995) The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 122:561–568 Diabetes Control and Complications Trial Research Group (1995) The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 122:561–568
18.
Zurück zum Zitat Fukuda M, Tanaka A, Tahara Y et al (1988) Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 37:81–88PubMed Fukuda M, Tanaka A, Tahara Y et al (1988) Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 37:81–88PubMed
19.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517–523 The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517–523
20.
Zurück zum Zitat Nakanishi K, Kobayashi T, Inoko H, Tsuji K, Murase T, Kosaka K (1995) Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44:1334–1339PubMed Nakanishi K, Kobayashi T, Inoko H, Tsuji K, Murase T, Kosaka K (1995) Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44:1334–1339PubMed
21.
Zurück zum Zitat Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26:832–836PubMed Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26:832–836PubMed
22.
Zurück zum Zitat Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes 53:250–264PubMed Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes 53:250–264PubMed
23.
Zurück zum Zitat Ido Y, Vindigni A, Chang K et al (1997) Prevention of vascular and nerve dysfunction in diabetic rats by C-peptide. Science 277:563–566PubMedCrossRef Ido Y, Vindigni A, Chang K et al (1997) Prevention of vascular and nerve dysfunction in diabetic rats by C-peptide. Science 277:563–566PubMedCrossRef
24.
Zurück zum Zitat Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J (2000) Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 17:181–189PubMedCrossRef Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J (2000) Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 17:181–189PubMedCrossRef
25.
Zurück zum Zitat Matsumoto S, Okitsu T, Iwanaga Y et al (2005) Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 365:1642–1644PubMedCrossRef Matsumoto S, Okitsu T, Iwanaga Y et al (2005) Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 365:1642–1644PubMedCrossRef
Metadaten
Titel
Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy—a nationwide 5-year-study in Japan
verfasst von
Y. Murase
A. Imagawa
T. Hanafusa
H. Iwahashi
Y. Uchigata
A. Kanatsuka
E. Kawasaki
T. Kobayashi
A. Shimada
I. Shimizu
T. Maruyama
H. Makino
Publikationsdatum
01.03.2007
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 3/2007
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0575-y

Weitere Artikel der Ausgabe 3/2007

Diabetologia 3/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.